Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANIL K SOOD and ROBERT COLEMAN.
ANIL K SOOD
Connection Strength
15.679
ROBERT COLEMAN
  1. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
    View in: PubMed
    Score: 0.765
  2. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43.
    View in: PubMed
    Score: 0.426
  3. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17.
    View in: PubMed
    Score: 0.401
  4. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol. 2010 Feb; 116(2):155-6.
    View in: PubMed
    Score: 0.357
  5. Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep. 2006 Nov; 8(6):455-64.
    View in: PubMed
    Score: 0.285
  6. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031.
    View in: PubMed
    Score: 0.244
  7. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
    View in: PubMed
    Score: 0.206
  8. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
    View in: PubMed
    Score: 0.200
  9. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
    View in: PubMed
    Score: 0.198
  10. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
    View in: PubMed
    Score: 0.198
  11. Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor a Blockade in Uterine Cancer. Clin Cancer Res. 2021 08 01; 27(15):4449.
    View in: PubMed
    Score: 0.198
  12. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4454.
    View in: PubMed
    Score: 0.198
  13. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.193
  14. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.191
  15. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
    View in: PubMed
    Score: 0.188
  16. Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther. 2020 11; 19(11):2396-2406.
    View in: PubMed
    Score: 0.186
  17. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.
    View in: PubMed
    Score: 0.183
  18. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.181
  19. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol Oncol. 2020 05; 157(2):386-391.
    View in: PubMed
    Score: 0.179
  20. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589.
    View in: PubMed
    Score: 0.176
  21. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther. 2020; 21(2):147-156.
    View in: PubMed
    Score: 0.175
  22. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
    View in: PubMed
    Score: 0.172
  23. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019 07 16; 33(7).
    View in: PubMed
    Score: 0.172
  24. Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin Cancer Res. 2019 May 15; 25(10):3194.
    View in: PubMed
    Score: 0.170
  25. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
    View in: PubMed
    Score: 0.168
  26. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 01; 20(1):e15-e28.
    View in: PubMed
    Score: 0.165
  27. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490.
    View in: PubMed
    Score: 0.163
  28. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.162
  29. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol. 2018; 10:1758835918778483.
    View in: PubMed
    Score: 0.159
  30. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018; 7:326.
    View in: PubMed
    Score: 0.156
  31. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
    View in: PubMed
    Score: 0.154
  32. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.
    View in: PubMed
    Score: 0.154
  33. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
    View in: PubMed
    Score: 0.151
  34. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
    View in: PubMed
    Score: 0.151
  35. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
    View in: PubMed
    Score: 0.150
  36. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123.
    View in: PubMed
    Score: 0.146
  37. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun; 12(12):1439-56.
    View in: PubMed
    Score: 0.137
  38. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther. 2016 06; 15(6):1344-52.
    View in: PubMed
    Score: 0.136
  39. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016 Mar; 56:131-143.
    View in: PubMed
    Score: 0.135
  40. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2677-86.
    View in: PubMed
    Score: 0.133
  41. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 01; 121(19):3444-51.
    View in: PubMed
    Score: 0.131
  42. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015 Aug; 138(2):223-6.
    View in: PubMed
    Score: 0.130
  43. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97.
    View in: PubMed
    Score: 0.128
  44. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475.
    View in: PubMed
    Score: 0.128
  45. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar; 34(1):19-40.
    View in: PubMed
    Score: 0.127
  46. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015 Apr; 12(4):239-45.
    View in: PubMed
    Score: 0.127
  47. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65.
    View in: PubMed
    Score: 0.126
  48. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.
    View in: PubMed
    Score: 0.124
  49. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2015 Mar 01; 21(5):955-61.
    View in: PubMed
    Score: 0.124
  50. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
    View in: PubMed
    Score: 0.121
  51. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9.
    View in: PubMed
    Score: 0.121
  52. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29.
    View in: PubMed
    Score: 0.119
  53. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8.
    View in: PubMed
    Score: 0.119
  54. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.119
  55. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.
    View in: PubMed
    Score: 0.119
  56. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.
    View in: PubMed
    Score: 0.119
  57. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50.
    View in: PubMed
    Score: 0.119
  58. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55.
    View in: PubMed
    Score: 0.118
  59. Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan; 132(1):166-75.
    View in: PubMed
    Score: 0.116
  60. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
    View in: PubMed
    Score: 0.115
  61. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr; 10(4):211-24.
    View in: PubMed
    Score: 0.110
  62. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther. 2013 Feb; 13(2):283-94.
    View in: PubMed
    Score: 0.108
  63. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
    View in: PubMed
    Score: 0.108
  64. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012 Nov 10; 30(32):4026-34.
    View in: PubMed
    Score: 0.107
  65. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii.
    View in: PubMed
    Score: 0.105
  66. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9.
    View in: PubMed
    Score: 0.102
  67. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):345-7.
    View in: PubMed
    Score: 0.102
  68. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.100
  69. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.
    View in: PubMed
    Score: 0.099
  70. Therapeutic advances in women's cancers. Front Biosci (Schol Ed). 2011 01 01; 3(1):82-97.
    View in: PubMed
    Score: 0.095
  71. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.
    View in: PubMed
    Score: 0.095
  72. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15; 10(12):1306-14.
    View in: PubMed
    Score: 0.095
  73. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.
    View in: PubMed
    Score: 0.093
  74. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
    View in: PubMed
    Score: 0.092
  75. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
    View in: PubMed
    Score: 0.092
  76. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010 Apr 15; 116(8):1918-25.
    View in: PubMed
    Score: 0.090
  77. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.
    View in: PubMed
    Score: 0.090
  78. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr; 9(4):985-95.
    View in: PubMed
    Score: 0.090
  79. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May; 11(5):465-75.
    View in: PubMed
    Score: 0.090
  80. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010 Mar; 10(3):431-7.
    View in: PubMed
    Score: 0.090
  81. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.
    View in: PubMed
    Score: 0.089
  82. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.
    View in: PubMed
    Score: 0.088
  83. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.
    View in: PubMed
    Score: 0.086
  84. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
    View in: PubMed
    Score: 0.086
  85. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.085
  86. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009 Jun 15; 115(12):2684-92.
    View in: PubMed
    Score: 0.085
  87. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600.
    View in: PubMed
    Score: 0.085
  88. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.085
  89. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53.
    View in: PubMed
    Score: 0.084
  90. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.082
  91. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
    View in: PubMed
    Score: 0.081
  92. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
    View in: PubMed
    Score: 0.080
  93. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10.
    View in: PubMed
    Score: 0.078
  94. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr; 5(4):194-204.
    View in: PubMed
    Score: 0.078
  95. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007 Dec 15; 13(24):7487-95.
    View in: PubMed
    Score: 0.077
  96. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.
    View in: PubMed
    Score: 0.076
  97. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15; 13(14):4209-17.
    View in: PubMed
    Score: 0.075
  98. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68.
    View in: PubMed
    Score: 0.073
  99. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 01; 67(1):281-8.
    View in: PubMed
    Score: 0.072
  100. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
    View in: PubMed
    Score: 0.072
  101. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006 Sep 01; 66(17):8633-9.
    View in: PubMed
    Score: 0.070
  102. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
    View in: PubMed
    Score: 0.070
  103. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.
    View in: PubMed
    Score: 0.070
  104. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother. 2005 Jun; 6(7):1269-75.
    View in: PubMed
    Score: 0.065
  105. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
    View in: PubMed
    Score: 0.061
  106. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344.
    View in: PubMed
    Score: 0.057
  107. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
    View in: PubMed
    Score: 0.054
  108. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.
    View in: PubMed
    Score: 0.052
  109. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.050
  110. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4).
    View in: PubMed
    Score: 0.048
  111. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.
    View in: PubMed
    Score: 0.044
  112. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
    View in: PubMed
    Score: 0.043
  113. Advancing Drug Development in Gynecologic Malignancies. Clin Cancer Res. 2019 08 15; 25(16):4874-4880.
    View in: PubMed
    Score: 0.042
  114. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.
    View in: PubMed
    Score: 0.042
  115. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526.
    View in: PubMed
    Score: 0.041
  116. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.
    View in: PubMed
    Score: 0.041
  117. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.040
  118. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
    View in: PubMed
    Score: 0.039
  119. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.035
  120. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6.
    View in: PubMed
    Score: 0.034
  121. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol. 2016 May; 141(2):260-263.
    View in: PubMed
    Score: 0.034
  122. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.
    View in: PubMed
    Score: 0.033
  123. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8.
    View in: PubMed
    Score: 0.032
  124. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19.
    View in: PubMed
    Score: 0.032
  125. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.
    View in: PubMed
    Score: 0.026
  126. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
    View in: PubMed
    Score: 0.026
  127. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7.
    View in: PubMed
    Score: 0.025
  128. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.025
  129. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.
    View in: PubMed
    Score: 0.025
  130. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
    View in: PubMed
    Score: 0.024
  131. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.
    View in: PubMed
    Score: 0.023
  132. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep; 114(3):431-6.
    View in: PubMed
    Score: 0.021
  133. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
    View in: PubMed
    Score: 0.021
  134. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6.
    View in: PubMed
    Score: 0.018
  135. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
    View in: PubMed
    Score: 0.018
  136. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.